Table 5.
REL Gene Amplification in Human Lymphoma/Leukemia
| Lymphoma/Leukemia Type | % Amplified REL (Total Cases Analyzed) | References |
|---|---|---|
| B cell malignancies | ||
| Hodgkin’s | 46 (175) | 101, 188-192 |
| DLBCL | 15 (1379) | 90, 91, 94, 118, 193-207 |
| Follicular | 17 (310) | 99, 193, 197, 208-212 |
| Primary mediastinal | 21 (136) | 91, 118, 199, 202, 213, 214 |
| Cutaneous B cell | 63 (31) | 215 |
| CLL | 5 (525) | 193, 211, 216-219 |
| Lymphoplasmacytic | 10 (10) | 211 |
| Burkitt’s | 7 (45) | 193, 220, 221 |
| Marginal zone | 7 (42) | 195, 211 |
| Pythorax associated | 28 (7) | 198 |
| T cell malignancies | ||
| Peripheral T cell | 11 (47) | 222 |
| Cutaneous CD30+ anaplastic large cell | 75 (8) | 223 |
| Natural killer T cell | 40 (5) | 224 |
CLL = chronic lymphocytic leukemia; DLBCL = diffuse large B cell lymphoma.